Cashu
Arcturus Therapeutics: Leading Innovations in mRNA Amidst Dynamic Biotechnology Landscape
25 days ago
Stocks
Health Care
arct
Arcturus Therapeutics Holdings
NASDAQ: ARCT
+0.28 (+4.03%)
7.105
USD
At close at Dec 05, 21:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
193.61M
Dividend Yield
0.00%
P/E Ratio
-2.90
EPS
-3.01
Revenue
152.31M
Avg. Volume
866.92K
About
What does ARCT do?
Arcturus Therapeutics, based in San Diego, develops mRNA medicines and vaccines for infectious diseases and rare liver and respiratory conditions, employing 180 staff since its IPO in May 2013. Its COVID-19 vaccine candidate is currently in Phase II clinical trials, utilizing its STARR technology for sustained protein expression.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.